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BiomarkerNeuropeptide Y and surgical recovery
We read with interest Enman et al.'s recent publication on
Neuropeptide Y (NPY) as a therapeutic target for stress-related
psychiatric diseases (Enman et al., 2015). They observe that NPY
has the potential to provide novel pharmacological therapy for
stress-related psychiatric diseases and may have few peripheral
side-effects and drugedrug interactions. Moreover, despite its
short half-life, NPY has a lasting effect. Enman et al. discuss a
number of animal studies in order to lay the rationale for NPY as a
pharmacological therapy for stress-related disease and cite two
clinical trials that are currently underway.
Their paper provides an excellent review of NPY and its role in
anxiety, depression and post-traumatic stress disorder (PTSD).
Insight into the role of NPY in the neurobiology of stress is devel-
oped through the discussion of multiple animal models. Rodents
that are genetically deﬁcient in NPY are phenotypically anxious but
this phenotype can be modiﬁed through the administration of NPY,
especially when administered in speciﬁc parts of the brain (namely
the amygdala, the hippocampus, the locus coeruleus, and the lateral
septum). Animal models demonstrate that the roles of NPYDOI of original article: http://dx.doi.org/10.1016/j.ynstr.2015.05.003.
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Activation of Y1 and Y2 receptors resulted in undesirable effects.
Furthermore, NPY does not readily cross the blood brain barrier.
These qualities of NPY pose additional challenges in the formula-
tion of an NPY therapeutic agent.
More broadly, the animal model evidence Enman et al. present
may be applied to examine how NPY modiﬁes the neurobiology of
stress via the Hypothalamus-Pituitary-Adrenal (HPA) axis. Enman
et al. provide a putative model of this modiﬁcation and suggest that
it may occur directly on the corticotrophin releasing hormone
(CRH)-ergic or the GABA-ergic neurons of the hypothalamus, the
noradrenergic neurons of the locus coeruleus, or via glutaminergic
neurons projecting from the basolateral amygdala into the hypo-
thalamus. Regardless of the neural circuitry, it is clear that NPY acts
on the HPA axis before the adenohypophysis releases ACTH.
Enman et al. highlighted the role of HPY as a “functional brake”
on the excitatory effects of pro-stress neurotransmitters, such as
CRH and Norepinephrine (NE). While NPY possesses an inhibitory
role, such as inhibiting the release of NE, its effects may be coun-
terintuitive. The inhibition of NE prevents its depletion by pre-
venting excessive secretion while maintaining its effectiveness for
maximal impact (Li et al., 2012; Han et al., 1987). NPY, therefore,
achieves potentiation through inhibition (Han et al., 1987). Under-
standing the function of NPY in such a context may explain the
mechanism of diminished CRH levels following electroconvulsive
therapy (ECT) as reported by Enman et al. The reported decrease in
CRH following ECT may have resulted not only from inhibition by
NPY, but also from its potentiating effects, such as preventing
excessive secretion of pro-stress neurotransmitters while
increasing its effectiveness. The potentiating effects of NPY may be
relevant to psychological resilience.
While Enman et al. make a strong case that NPY is a potential
pharmacological target, there is yet another a large body of evi-
dence that suggests NPY could be a useful endogenous biological
marker for psychological resilience (Russo et al., 2012). Psycho-
logical resilience is characterised by the ability to accept circum-
stances that cannot be changed and adapt to signiﬁcant changes in
the environment (Folkman, 2010). As such it is intimately related to
stress and state anxiety. Along with other potential biomarkers,
namely the androgens dehydroepiandrosterone (DHEA) and
testosterone, studies consistently show that NPY levels are elevated
in psychologically resilient individuals. Its precise role in resiliencender the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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The clinical implications are manifold, especially in surgical
recovery. Surgery is a highly stressful event both physiologically
and psychologically, and it has been proposed that there is a psy-
chological mediation of recovery (Kehlet & Slim, 2012; Janis, 1958),
which is supported by a substantial amount of evidence (Walburn
et al., 2009; Mavros et al., 2011; Munafo & Stevenson, 2001).
Some patients exhibit a diminished stress response to surgery and
more rapid recovery than others. These patients are surgically
resilient (Graham & Becerril-Martinez, 2014).
NPY offers a potentially valuable resilience biomarker. As such,
we believe that it could provide a stable endogenous biological
marker for resilience that would potentially be clinically valuable to
measure prior to surgery (Graham & Becerril-Martinez, 2014). This
would allow the development of patient-speciﬁc enhanced post-
operative recovery protocols, which would enhance the current
surgical paradigm of fast-track or enhanced recovery through
individualising patient allocation (Kehlet & Slim, 2012). Ensuring
patient expectations are well managed and that patients under-
going elective surgery are relatively ﬁt and healthy prior to surgery
may prove to be a more clinically prudent than administering NPY
to patients without any pre-operative stress-related psychological
disease.
We agree with Enman et al. to some extent insofar as NPY is a
potential therapeutic target. Resilience itself has been shown to be
an effective therapeutic target in patients without a psychiatric
disease, and we argue that such strategies can be used to person-
alise peri-operative care and improve surgical outcomes. An NPY-
based screening test to identify surgical resilience pre-operatively
would have a large impact in elective surgery allowing for tar-
geted prehabilitation interventions and possibly also in recovery
strategies after emergency or trauma surgery. A number of studies
have reported behavioural/psychological (Morgan et al., 2000),
physical (Coiro et al., 2011; Han et al., 2011), and dietary in-
terventions (Huang et al., 2011) that increase NPY levels. Beyond
screening, interventions may be considered to enhance levels of
NPY in a perioperative surgical context.
It is clear that NPY has much clinical potential. While it may be
beneﬁcial as a therapy for stress-related psychiatric diseases, NPY
has a much broader potential when considered from theperspective of psychological resilience. More research is needed on
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